Humacyte Stock Based Compensation from 2010 to 2024

HUMAW Stock

USD 1.69 0.11 6.96%

Humacyte Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2010-12-31

Previous Quarter

6.8 M

Current Value

7.1 M

Quarterly Volatility

1.6 M

Credit Downgrade

Yuan Drop

Covid

Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 M, Interest Expense of 1.1 M or Selling General Administrative of 21.1 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or PTB Ratio of 22.77. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.

Check out the analysis of Humacyte Correlation against competitors.

For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.

Latest Humacyte's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Humacyte over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Humacyte's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Humacyte's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Humacyte Stock Based Compensation Regression Statistics

	Arithmetic Mean	5,301,999
	Geometric Mean	5,125,130
	Coefficient Of Variation	30.80
	Mean Deviation	1,207,731
	Median	4,457,000
	Standard Deviation	1,633,192
	Sample Variance	2.7T
	Range	5.7M
	R-Value	0.63
	Mean Square Error	1.7T
	R-Squared	0.40
	Significance	0.01
	Slope	231,732
	Total Sum of Squares	37.3T

Humacyte Stock Based Compensation History

	2024	7.1 M
	2023	6.8 M
	2022	6.2 M
	2021	10.1 M
	2020	4.7 M

Other Fundumenentals of Humacyte

Stock Based Compensation To Revenue

Humacyte Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Long Term Debt	Capital Surpluse	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Current Deferred Revenue
Total Assets		0.49	-0.87	-0.11	-0.45	-0.13	-0.23	0.97	0.75	0.0	0.34	0.0	0.55	0.0	0.41	0.22	0.81	-0.05	-0.04
Total Stockholder Equity	0.49		-0.56	0.37	0.05	0.55	-0.96	0.39	0.12	0.22	-0.11	0.22	-0.06	0.22	-0.07	0.08	0.02	-0.02	0.14
Net Debt	-0.87	-0.56		-0.26	0.51	-0.13	0.3	-0.83	-0.76	-0.46	-0.1	-0.46	-0.31	-0.46	-0.25	-0.26	-0.6	0.13	-0.24
Retained Earnings	-0.11	0.37	-0.26		-0.34	0.91	-0.39	-0.29	-0.25	0.86	-0.89	0.86	-0.82	0.86	-0.81	-0.19	-0.59	-0.38	0.87
Accounts Payable	-0.45	0.05	0.51	-0.34		-0.05	-0.22	-0.37	-0.54	-0.44	0.35	-0.44	0.0	-0.44	0.19	-0.43	-0.31	-0.17	-0.28
Net Receivables	-0.13	0.55	-0.13	0.91	-0.05		-0.62	-0.33	-0.49	0.61	-0.84	0.61	-0.85	0.61	-0.83	-0.41	-0.67	-0.47	0.8
Total Liab	-0.23	-0.96	0.3	-0.39	-0.22	-0.62		-0.12	0.14	-0.14	0.21	-0.14	0.21	-0.14	0.19	0.0	0.23	-0.02	-0.11
Total Current Assets	0.97	0.39	-0.83	-0.29	-0.37	-0.33	-0.12		0.84	-0.09	0.53	-0.09	0.72	-0.09	0.61	0.32	0.91	0.07	-0.22
Common Stock	0.75	0.12	-0.76	-0.25	-0.54	-0.49	0.14	0.84		0.14	0.5	0.14	0.74	0.14	0.67	0.69	0.85	0.38	-0.31
Net Tangible Assets	0.0	0.22	-0.46	0.86	-0.44	0.61	-0.14	-0.09	0.14		-0.62	1.0	-0.52	1.0	-0.46	0.1	-0.31	-0.23	0.72
Long Term Debt	0.34	-0.11	-0.1	-0.89	0.35	-0.84	0.21	0.53	0.5	-0.62		-0.62	0.93	-0.62	0.97	0.27	0.74	0.3	-0.79
Capital Surpluse	0.0	0.22	-0.46	0.86	-0.44	0.61	-0.14	-0.09	0.14	1.0	-0.62		-0.52	1.0	-0.46	0.1	-0.31	-0.23	0.72
Net Invested Capital	0.55	-0.06	-0.31	-0.82	0.0	-0.85	0.21	0.72	0.74	-0.52	0.93	-0.52		-0.52	0.96	0.5	0.9	0.45	-0.78
Long Term Investments	0.0	0.22	-0.46	0.86	-0.44	0.61	-0.14	-0.09	0.14	1.0	-0.62	1.0	-0.52		-0.46	0.1	-0.31	-0.23	0.72
Short Long Term Debt	0.41	-0.07	-0.25	-0.81	0.19	-0.83	0.19	0.61	0.67	-0.46	0.97	-0.46	0.96	-0.46		0.46	0.8	0.41	-0.78
Capital Stock	0.22	0.08	-0.26	-0.19	-0.43	-0.41	0.0	0.32	0.69	0.1	0.27	0.1	0.5	0.1	0.46		0.38	0.9	-0.55
Net Working Capital	0.81	0.02	-0.6	-0.59	-0.31	-0.67	0.23	0.91	0.85	-0.31	0.74	-0.31	0.9	-0.31	0.8	0.38		0.19	-0.46
Short Term Debt	-0.05	-0.02	0.13	-0.38	-0.17	-0.47	-0.02	0.07	0.38	-0.23	0.3	-0.23	0.45	-0.23	0.41	0.9	0.19		-0.75
Current Deferred Revenue	-0.04	0.14	-0.24	0.87	-0.28	0.8	-0.11	-0.22	-0.31	0.72	-0.79	0.72	-0.78	0.72	-0.78	-0.55	-0.46	-0.75

Click cells to compare fundamentals

About Humacyte Financial Statements

Humacyte investors use historical fundamental indicators, such as Humacyte's Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Humacyte. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	6.8 M	7.1 M
Stock Based Compensation To Revenue	3.56	3.17

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Humacyte Stock Based Compensation from 2010 to 2024

Latest Humacyte's Stock Based Compensation Growth Pattern

Humacyte Stock Based Compensation Regression Statistics

Humacyte Stock Based Compensation History

Other Fundumenentals of Humacyte

Humacyte Stock Based Compensation component correlations

About Humacyte Financial Statements

Also Currently Popular

Additional Tools for Humacyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY